Information Provided By: 
Fly News Breaks for June 7, 2016
SRPT
Jun 7, 2016 | 07:57 EDT
After the FDA requested additional data on Sarepta's DMD treatment, eteplirsen, JMP Securities says an expert with whom it consulted still believes that the drug has only a 10% chance of being approved.The firm does not expect the FDA to approve the drug, and it keeps a $10 price target and Underperform rating on the name.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
